Corvus plans in the second stage of Soquelitinib’s experience in atopic dermatitis, targeting 200 patients with a 12 -week treatment window

Corvus plans in the second stage of Soquelitinib’s experience in atopic dermatitis, targeting 200 patients with a 12 -week treatment window



[og_img]

Source link